Cost-effectiveness of annual trivalent inactivated influenza vaccine program by age and risk status

Abstract

Objective: To evaluate the cost-effectiveness of annual trivalent inactivated influenza vaccine (IIV3) under the context of Zhejiang province.

Methods: A state transition simulation model was constructed to estimate the health and economic outcomes of IIV3 vaccination program compared to no vaccination for hypothetical cohorts of Zhejiang province stratified by age and risk status. Model input parameters were chosen based on published literatures and expert advices. The analysis used societal perspectives and a one-year time horizon, and permanent outcomes were also included. The primary outcome was the incremental cost-effectiveness ratio (ICER), with expression of US dollars per quality adjusted life years (QALYs) gained.

Results: In subgroups not at high risk for influenza-related complications (non-high risk subgroup), ICER ranged from \$6 268/QALY (for adults aged 50-64 years) to \$11 260/QALY (for children aged from 6 months to 4 years). In subgroups at high risk for influenza-related complications (high risk subgroup), ICER ranged from cost-saving (adults aged ≥65 years) to \$5 260/QALY (for children aged from 6 months to 4 years). ICER were most sensitive to changes in probability of influenza illness, cost of hospitalization, and probability of death for adults aged 18-49 years with non-high risk status.

Conclusions: ICERs of annual influenza vaccination varied by age and risk status but were less than the Gross Domestic Product (GDP) per capita of Zhejiang province (\$17 745 in 2023), which remained cost-effective for all-age and different risk status groups from a societal perspective.

Keywords

Influenza / Vaccination / Cost-effectiveness / Trivalent inactivated influenza vaccine / Risk

Conflict of interest statement

The authors declare that they have no competing interests.

Funding

This study was funded by Medical and Health Science and Technology Project of Zhejiang province (Grant number: 2023KY633).

Authors’ contributions

YH and ZY developed the specific study protocol, constructed the model for cost effectiveness analysis. CJ collaborated in the study protocol and in the construction and refinement of the model. JZ and YX contributed to the collection of data required for the input parameters. YH and ZY initiated the study design, supervised the project, and directed the analysis and manuscript writing. All authors had carefully revised the draft of the manuscript.

Publisher’s note

The Publisher of the Journal remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Edited by Lei Y, Pan Y, Zhang Q

Acknowledgments

We would like to thank the following representatives of various organizations (School of Medicine of Zhejiang University, Sir Run Run Shaw Hospital of Zhejiang University, Ningbo Municipal Centers of Disease Control and Prevention, Hangzhou First People's Hospital) who formed our local expert panel and participated in our consultative meetings and interviews and contributed technical support and expert opinions.

References

[1] Budd AP, Beacham L, Smith CB, Garten RJ, Reed C, Kniss K, et al. Birth cohort effects in influenza surveillance data: Evidence that first influenza infection affects later influenza-associated illness. J Infect Dis 2019; 220(5): 820-829.

[2] Chow EJ, Davis CT, Abd Elal AI, Alabi N, Azziz-Baumgartner E, Barnes J, et al. Update: Influenza activity-United States and worldwide, May 20-October 13, 2018. MMWR Morb Mortal Wkly Rep 2018; 67(42): 1178-1185.

[3] Kumar V. Influenza in children. Indian J Pediatr 2017; 84(2): 139-143.

[4] Wang Q, Yue N, Zheng M, Wang D, Duan C, Yu X, et al. Influenza vaccination coverage of population and the factors influencing influenza vaccination in mainland China: A meta-analysis. Vaccine 2018; 36(48): 7262-7269.

[5] Wang Q, Yang L, Liu C, Jin H, Lin L. Estimated incidence of seasonal influenza in China from 2010 to 2020 using a multiplier model. JAMA Netw Open 2022; 5(4): e227423.

[6] Ortiz JR, Perut M, Dumolard L, Wijesinghe PR, Jorgensen P, Ropero AM, et al. A global review of national influenza immunization policies: Analysis of the 2014 WHO/UNICEF joint reporting form on immunization. Vaccine 2016; 34(45): 5400-5405.

[7] Niu D, Xu J, Liu J, Gong R, Shi J, Wu Q. Characteristics and factors of repeated influenza vaccination among elderly individuals in Shanghai, China from 2020 to 2022. Hum Vaccin Immunother 2024; 20(1): 2364480.

[8] Deng P, Xue C, Yang T, Zheng B, Liu W, Yang L, et al. Epidemiological analysis of influenza vaccination coverage in Pudong New Area, Shanghai (2013-2023): Implications for influenza vaccination strategies. Hum Vaccin Immunother 2024; 20(1): 2412887.

[9] Lv M, Fang R, Wu J, Pang X, Deng Y, Lei T, et al. The free vaccination policy of influenza in Beijing, China: The vaccine coverage and its associated factors. Vaccine 2016; 34(18): 2135-2140.

[10] Budd AP, Beacham L, Smith CB, Garten RJ, Reed C, Kniss K, et al. Birth cohort effects in influenza surveillance data: Evidence that first influenza infection affects later influenza-associated illness. J Infect Dis 2019; 220(5): 820-829.

[11] Minney-Smith CA, Selvey LA, Levy A, Smith DW. Post-pandemic influenza A/H1N1pdm09 is associated with more severe outcomes than A/H3N2 and other respiratory viruses in adult hospitalisations. Epidemiol Infect 2019; 147: e310.

[12] Sumner KM, Masalovich S, O'Halloran A, Holstein R, Reingold A, Kirley PD, et al. Severity of influenza-associated hospitalisations by influenza virus type and subtype in the USA, 2010-19: A repeated crosssectional study. Lancet Microbe 2023; 4(11): e903-e912.

[13] Lytras T, Andreopoulou A, Gkolfinopoulou K, Mouratidou E, Tsiodras S. Association between type-specific influenza circulation and incidence of severe laboratory-confirmed cases; which subtype is the most virulent? Clin Microbiol Infect 2020; 26(7): 922-927.

[14] Zimmerman RK, Nowalk MP, Chung J, Jackson ML, Jackson LA, Petrie JG, et al. 2014-2015 influenza vaccine effectiveness in the United States by vaccine type. Clin Infect Dis 2016; 63(12): 1564-1573.

[15] China Clinical Practice Guidelines Alliance Methodology Committee. Practice guideline of influenza vaccination and antiviral drugs use in children (2024 editon). Zhonghua Yi Xue Za Zhi 2024; 104(40): 3705-3725.

[16] Centers for Disease Control and Prevention. Burden estimates for the 2017-2018 influenza season. [Online]. Available from: https://www.cdc.gov/flu/about/burden/2017-2018.htm. [Accessed on 20 November 2024].

[17] Zimmerman RK, Lauderdale DS, Tan SM, Wagener DK. Prevalence of high-risk indications for influenza vaccine varies by age, race, and income. Vaccine 2010; 28(39): 6470-6477.

[18] Centers for Disease Control and Prevention. Influenza hospitalization surveillance network (FluSurv-NET). [Online]. Available from: https://www.cdc.gov/flu/weekly/influenza-hospitalization-surveillance.htm. [Accessed on 20 November 2024].

[19] Jantarabenjakul W, Paprad T, Paprad T, Anugulruengkitt S, Pancharoen C, Puthanakit T, et al. Neurological complications associated with influenza in hospitalized children. Influenza Other Respir Viruses 2023; 17(1): e13075.

[20] Moore DL, Vaudry W, Scheifele DW, Halperin SA, Déry P, Ford-Jones E, et al. Surveillance for influenza admissions among children hospitalized in Canadian immunization monitoring program active centers, 20032004. Pediatrics 2006; 118(3): e610-e619.

[21] Moro PL, Woo EJ, Marquez P, Cano M. Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011-2019. Vaccine 2020; 38(37): 5923-5926.

[22] Muhammad R, Haber P, Broder K, Leroy Z, Ball R, Braun MM, et al. Adverse events following trivalent inactivated influenza vaccination in children: Analysis of the vaccine adverse event reporting system. Pediatr Infect Dis J 2011; 30(1): e1-e8.

[23] Veroniki AA, Thirugnanasampanthar SS, Konstantinidis M, Dourka J, Ghassemi M, Neupane D, et al. Trivalent and quadrivalent seasonal influenza vaccine in adults aged 60 and older: A systematic review and network meta-analysis. BMJ Evid Based Med 2024; 29(4): 239-254.

[24] Carregaro RL, Roscani ANCP, Raimundo ACS, Ferreira L, Vanni T, da Graça Salomão M, et al. Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: An overview of systematic reviews. BMC Infect Dis 2023; 23(1): 563.

[25] Wang Y, Chen L, Cheng F, Biggerstaff M, Situ S, Zhou S, et al. Economic burden of influenza illness among children under 5 years in Suzhou, China: Report from the cost surveys during 2011/12 to 2016/17 influenza seasons. Vaccine 2021; 39(8): 1303-1309.

[26] Yang J, Jit M, Leung KS, Zheng YM, Feng LZ, Wang LP, et al. The economic burden of influenza-associated outpatient visits and hospitalizations in China: A retrospective survey. Infect Dis Poverty 2015; 4: 44.

[27] Zhang H, Garcia C, Yu W, Knoll MD, Lai X, Xu T, et al. National and provincial impact and cost-effectiveness of Haemophilus influenzae type b conjugate vaccine in China: A modeling analysis. BMC Med 2021; 19(1): 181.

[28] Yu W, Lu M, Wang H, Rodewald L, Ji S, Ma C, et al. Routine immunization services costs and financing in China, 2015. Vaccine 2018; 36(21): 3041-3047.

[29] Hart RJ, Stevenson MD, Smith MJ, LaJoie AS, Cross K. Cost-effectiveness of strategies for offering influenza vaccine in the pediatric emergency department. JAMA Pediatr 2018; 172(1): e173879.

[30] Yang J, Jit M, Zheng Y, Feng L, Liu X, Wu JT, et al. The impact of influenza on the health related quality of life in China: An EQ-5D survey. BMC Infect Dis 2017; 17(1): 686.

[31] Prosser LA, Payne K, Rusinak D, Shi P, Uyeki T, Messonnier M. Valuing health across the lifespan: Health state preferences for seasonal influenza illnesses in patients of different ages. Value Health 2011; 14(1): 135-143.

[32] Yang S, Wang Q, Li T, Long J, Xiong Y, Feng L, et al. Effectiveness of influenza vaccine among the population in Chongqing, China, 20182022: A test negative design-based evaluation. Hum Vaccin Immunother 2024; 20(1): 2376821.

[33] Procter SR, Waterlow NR, Radhakrishnan S, van Leeuwen E, Meeyai A, Cooper BS, et al. Health impact and cost-effectiveness of vaccination using potential next-generation influenza vaccines in Thailand: A modelling study. BMJ Glob Health 2024; 9(11): e015837.

[34] Barbieri E, Wang Y, Cantarutti A, Scamarcia A, Cantarutti L, Corrao G, et al. Cost-effectiveness of influenza vaccination in healthy children: A 10-year population-based study. Vaccines (Basel) 2024; 12(10): 1113.

[35] Brydak L, Roiz J, Faivre P, Reygrobellet C. Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: A cost-effectiveness analysis. Clin Drug Investig 2012; 32(2): 73-85.

[36] Postma MJ, Bos JM, van Gennep M, Jager JC, Baltussen R, Sprenger MJ. Economic evaluation of influenza vaccination: Assessment for the Netherlands. Pharmacoeconomics 1999; 16(Suppl 1): 33-40.

[37] Hassan MZ, Jubayer Biswas MAA, Shirin T, Rahman M, Chowdhury F, Azziz-Baumgartner E, et al. Cost-effectiveness of seasonal influenza vaccination in WHO-defined high-risk populations in Bangladesh. J Glob Health 2024; 14: 04126.

[38] Salo H, Kilpi T, Sintonen H, Linna M, Peltola V, Heikkinen T. Cost-effectiveness of influenza vaccination of healthy children. Vaccine 2006; 24(23): 4934-4941.

[39] Newall AT, Scuffham PA, Kelly H, Harsley S, Macintyre CR. The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia. Vaccine 2008; 26(17): 2142-2153. doi: 10.1016/j.vaccine.2008.01.050. PMID: 18343537.

[40] Aballéa S, De Juanes JR, Barbieri M, Martin M, Chancellor J, Oyagüez I, et al. The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: A model-based analysis for Spain. Vaccine 2007; 25(39-40): 6900-6910.

[41] Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 2006; 35(2): 337-344.

[42] Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: A cost-effectiveness analysis. Am J Med 2005; 118(1): 68-77.

[43] Lee PY, Matchar DB, Clements DA, Huber J, Hamilton JD, Peterson ED. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med 2002; 137(4): 225-231.

[44] Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13(5): 437-452.

[45] George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making: Evidence from pharmaceutical reimbursement in australia (1991 to 1996). Pharmacoeconomics 2001; 19(11): 1103-1109.

[46] Bridges JF, Onukwugha E, Mullins CD. Healthcare rationing by proxy: Cost-effectiveness analysis and the misuse of the \$50,000 threshold in the US. Pharmacoeconomics 2010; 28(3): 175-184.

[47] Xu J, Zhou F, Reed C, Chaves SS, Messonnier M, Kim IK. Cost-effectiveness of seasonal inactivated influenza vaccination among pregnant women. Vaccine 2016; 34(27): 3149-3155.

[48] Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on cost-effectiveness in health and medicine. JAMA 2016; 316(10): 1093-1103.

[49] Avritscher EB, Cooksley CD, Geraci JM, Bekele BN, Cantor SB, Rolston KV, et al. Cost-effectiveness of influenza vaccination in working-age cancer patients. Cancer 2007; 109(11): 2357-2364.

[50] Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med 2006; 31(1): 72-79.